Within the realm of PPAR agents, the utilisation of nanomedicine as a carrier for PPARγ agent has been tested for the treatment of chronic liver disease and have shown to reduce liver fibrosis and inflammation [102]. This evidence concerns the gene PPARG and Hepatic fibrosis.